All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Cytomegalovirus (CMV) is a member of the herpes virus group which includes herpes simplex virus types 1 and 2; Varicella Zoster Virus, which causes chicken pox; and Epstein Barr virus, which causes infectious mononucleosis. These viruses remain dormant within the body over a long period. In humans, CMV is known as HCMV or human herpesvirus 5 (HHV-5). HHV-5 causes only a brief mononeucleosis-like malaise in immunocompetent adults, but may cause severe illness or death in immunosuppressed individuals. CMV pp65 is the early-late lower matrix phosphoprotein of CMV that may be relevant to the etiopathogenesis of scleroderma. CMV pp65 is a major constituent of the CMV virion bodies and is abundantly synthesized during lytic infection. In addition, the CMV pp65 protein is a frequent target for the exceptionally strong CMV-specific CD8(+) T cell response.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L094 | Human anti-pp65 (NLVPMVATV) T Cell Receptor, pMP71 | Cytomegalovirus (CMV) | Human | NLVPMVATV | retroviral vector | |||
TCR-L097 | Human anti-pp65 (NLVPMVATV) T Cell Receptor, pLXSN | CMV | Human | NLVPMVATV | HLA-A*0201 | retroviral vector | ||
TCR-L098 | Human anti-pp65 (KYQEFFWDANDIYRI) T Cell Receptor, pLZRS | CMV | Human | KYQEFFWDANDIYRI | HLA-DRB1*0101 | retroviral vector | ||
TCR-L099 | Human anti-pp65 (QYDPVAALF) T Cell Receptor, CSII-EF-MCS-IRES-hrGFP | CMV | Human | QYDPVAALF | lentiviral vector | |||
TCR-L100 | Human anti-pp65 (TPRVTGGAM) T Cell Receptor, pMP71 | CMV | Human | TPRVTGGAM | HLA-B7 | retroviral vector | ||
TCR-L101 | Human anti-pp65 (RPHERNGFTVL) T Cell Receptor, pMP71 | CMV | Human | RPHERNGFTVL | HLA-B7 | retroviral vector | ||
TCR-L093Z | Human anti-pp65 (aa495-453) T cell receptor, pCDTCR1 | Cytomegalovirus (CMV) | Human | NLVPMVATV | Lentiviral | |||
TCR-L096Z | Human anti-pp65 (aa495-503) T cell receptor, pCDTCR1 | CMV | Human | NLVPMVATV | HLA-A*0201 | Lentiviral | ||
TCR-L097Z | Human anti-pp65 (aa509-523) T cell receptor (Codon optimized), pCDTCR1 | CMV | Human | KYQEFFWDANDIYRI | HLA-DRB1*0101 | Lentiviral | ||
TCR-L098Z | Human anti-pp65 (aa341-349) T cell receptor, pCDTCR1 | CMV | Human | QYDPVAALF | Lentiviral | |||
TCR-L099Z | Human anti-pp65 (aa417-426) T cell receptor (Codon optimized and cysteine modified), pCDTCR1 | CMV | Human | TPRVTGGAM | HLA-B7 | Lentiviral | ||
TCR-L100Z | Human anti-pp65 (aa265-275) T cell receptor (Codon optimized and cysteine modified), pCDTCR1 | CMV | Human | RPHERNGFTVL | HLA-B7 | Lentiviral | ||
TCR-C212Z | Human anti-pp65 T cell receptor (RA14), pCDTCR1 | CMV | RA14 | Human | NLVPMVATV | HLA-A2 | Lentiviral | |
TCR-C213Z | Human anti-pp65 T cell receptor (12), pCDTCR1 | CMV | 12 | Human | IPSINVHHY | HLA-B35 | Lentiviral | |
TCR-C214Z | Human anti-pp65 T cell receptor (JG-9), pCDTCR1 | CMV | JG-9 | Human | NLVPMVATV | HLA-A*0201 | Lentiviral | |
TCR-C215Z | Human anti-pp65 T cell receptor (JG-33), pCDTCR1 | CMV | JG-33 | Human | NLVPMVATV | HLA-A*0201 | Lentiviral | |
TCR-C216Z | Human anti-pp65 T cell receptor (MD-19), pCDTCR1 | CMV | MD-19 | Human | YSEHPTFTSQY | HLA-A*0101 | Lentiviral | |
TCR-C217Z | Human anti-pp65 T cell receptor (BF-33/BF-38), pCDTCR1 | CMV | BF-33/BF-38 | Human | IPSINVHHY | HLA-B*3501 | Lentiviral | |
TCR-C218Z | Human anti-pp65 T cell receptor (Codon optimized), pCDTCR1 | CMV | Human | NLVPMVATV | HLA-A2.1 | Lentiviral | ||
TCR-C219Z | Human anti-pp65 T cell receptor (C7), pCDTCR1 | CMV | C7 | Human | NLVPMVATV | HLA-A2 | Lentiviral |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION